{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:22:07Z","timestamp":1763018527104,"version":"3.45.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jtct.2022.10.027","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T04:37:48Z","timestamp":1667536668000},"page":"113-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-0623","authenticated-orcid":false,"given":"Matthew P.","family":"Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7584-6850","authenticated-orcid":false,"given":"Mary Ellen","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7778","authenticated-orcid":false,"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7308-3260","authenticated-orcid":false,"given":"James K.","family":"Mangan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon R.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith W.","family":"Pratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9332-392X","authenticated-orcid":false,"given":"Colleen","family":"Timlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-8134","authenticated-orcid":false,"given":"Craig W.","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-1662","authenticated-orcid":false,"given":"Alison","family":"Carulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-796X","authenticated-orcid":false,"given":"Christopher","family":"Catania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-4307","authenticated-orcid":false,"given":"Lauren","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis M.","family":"Zebrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.10.027_bib0001","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/bmt.2017.8","article-title":"Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy","volume":"52","author":"Gyurkocza","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0002","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","article-title":"Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre registry analysis","volume":"2","author":"Nagler","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0003","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3324\/haematol.2009.013920","article-title":"Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia","volume":"95","author":"Craddock","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.10.027_bib0004","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan","volume":"13","author":"Oran","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0005","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"Schneidawind","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00432-015-2050-y","article-title":"Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation","volume":"142","author":"Pfrepper","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0007","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.bbmt.2009.07.008","article-title":"Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia","volume":"15","author":"Armistead","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0008","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.027_bib0009","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0010","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1704062","article-title":"Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor","volume":"31","author":"Sayer","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.2016.150326","article-title":"Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity transplantation for primary refractory acute myeloid leukemia","volume":"102","author":"Mohty","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.10.027_bib0012","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","article-title":"Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation","volume":"11","author":"Wong","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0013","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0014","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.1090","article-title":"Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.027_bib0015","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/cam4.880","article-title":"Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML\/MDS","volume":"5","author":"Chevallier","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.10.027_bib0016","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/cncr.23816","article-title":"Clofarabine combinations as acute myeloid leukemia salvage therapy","volume":"113","author":"Faderl","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.10.027_bib0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/leu.2015.226","article-title":"Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial","volume":"30","author":"Middeke","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.10.027_bib0018","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/cam4.2865","article-title":"Clofarabine, cytarabine, and mitoxantrone in refractory\/relapsed acute myeloid leukemia: high response rates and effective bridge to allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Gill","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.10.027_bib0019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1634\/theoncologist.2010-0220","article-title":"Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity","volume":"16","author":"Agura","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2022.10.027_bib0020","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1182\/blood-2011-06-358010","article-title":"Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies","author":"Magenau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.027_bib0021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bmt.2016.188","article-title":"A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Magenau","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0022","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/leu.2010.319","article-title":"Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia","volume":"25","author":"Farag","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.10.027_bib0023","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.V124.21.1239.1239","article-title":"Clofarabine busulfan conditioning improves outcomes in patients with active acute myelogenous leukemia undergoing allogeneic stem cell transplant [ASH abstract 732, December 6, 2014]","volume":"124","author":"Zebrowski","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.027_bib0024","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine \u00b1 fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"17","author":"Andersson","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0025","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.bbmt.2016.06.023","article-title":"Long-term outcomes after treatment with clofarabine\u2009\u00b1\u2009fludarabine with once-daily intravenous busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and myelodysplastic syndrome","volume":"22","author":"Alatrash","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0026","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.027_bib0027","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2022.10.027_bib0028","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Methodol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0029","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2022.10.027_bib0030","unstructured":"R Core Team. R: A language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"key":"10.1016\/j.jtct.2022.10.027_bib0031","unstructured":"Therneau T. A package for survival analysis in R. 2020. R package version 3.2-3. Available at: https:\/\/CRAN.R-project.org\/package=survival. Accessed 24 October 2020."},{"year":"2016","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham H","key":"10.1016\/j.jtct.2022.10.027_bib0032"},{"key":"10.1016\/j.jtct.2022.10.027_bib0033","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbmt.2016.11.001","article-title":"Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results","volume":"23","author":"Kebriaei","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0034","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.hoc.2010.02.003","article-title":"Hematopoietic stem cell transplantation for MDS","volume":"24","author":"Bartenstein","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2022.10.027_bib0035","first-page":"139","article-title":"Intensive chemotherapy for patients with high-risk myelodysplastic syndrome","volume":"72","author":"Beran","year":"2000","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0036","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.027_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0038","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.027_bib0039","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.10.027_bib0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0041","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0042","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.10.027_bib0043","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbmt.2003.10.006","article-title":"Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation","volume":"10","author":"Couriel","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.027_bib0044","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2141.2005.05614.x","article-title":"Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation","volume":"130","author":"P\u00e9rez-Sim\u00f3n","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.10.027_bib0045","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2010.01.010","article-title":"A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis","volume":"16","author":"Perkins","year":"2010","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:36Z","timestamp":1763003376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722017420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666636722017420"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.027","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}